- Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M CDC
- RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC STAT
- US study says treatment 90% effective against RSV in infants Medical Xpress
- CDC says new treatment for infant RSV infections ‘highly effective’ in preventing hospitalization WSB Atlanta
- Nirsevimab highly effective at preventing RSV hospitalization in infants, report shows Healio
Read More: Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory